Commonwealth Financial Services’s Quest Diagnostics DGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$286K Sell
1,226
-363
-23% -$83.9K 0.05% 187
2026
Q2
$337K Sell
1,589
-391
-20% -$76.7K 0.05% 195
2026
Q1
$388K Buy
1,980
+172
+10% +$33.4K 0.06% 144
2025
Q4
$314K Sell
1,808
-68
-4% -$12.4K 0.05% 163
2025
Q3
$357K Sell
1,876
-189
-9% -$33.5K 0.06% 148
2025
Q2
$371K Sell
2,065
-35
-2% -$6.08K 0.07% 135
2025
Q1
$355K Sell
2,100
-182
-8% -$29.9K 0.07% 135
2024
Q4
$344K Buy
2,282
+63
+3% +$9.8K 0.07% 133
2024
Q3
$342K Sell
2,219
-100
-4% -$14.9K 0.07% 132
2024
Q2
$322K Sell
2,319
-74
-3% -$10.1K 0.07% 129
2024
Q1
$330K Hold
2,393
– – 0.08% 128
2023
Q4
$330K Sell
2,393
-240
-9% -$31.6K 0.08% 127
2023
Q3
$321K Buy
+2,633
New +$351K 0.1% 127

Other funds holding DGX

Commonwealth Financial Services's DGX Position: Q3 2026 in Review

Commonwealth Financial Services reduced its Quest Diagnostics (DGX) stake by 23% in Q3 2026, selling an estimated $83.9K and leaving 1,226 shares worth $286K. The position accounts for 0.05% of the portfolio, ranked #187.

Commonwealth Financial Services first reported a position in DGX in Q3 2023 and has held it in 13 quarters since. The position peaked at $388K in Q1 2026. 266 funds tracked by Wall St. Rank hold DGX as of Q3 2026.

  • Commonwealth Financial Services held 1,226 shares of Quest Diagnostics worth $286K as of Q3 2026.
  • Commonwealth Financial Services sold 363 Quest Diagnostics shares in Q3 2026, an estimated $83.9K.
  • Quest Diagnostics made up 0.05% of Commonwealth Financial Services's portfolio in Q3 2026, its #187 holding.
  • Commonwealth Financial Services first reported a position in Quest Diagnostics in Q3 2023 and has held it in 13 quarters since.
  • Commonwealth Financial Services's Quest Diagnostics position peaked at $388K in Q1 2026.
  • 266 funds tracked by Wall St. Rank held Quest Diagnostics as of Q3 2026.

Based on Commonwealth Financial Services's 13F filing for Q3 2026, filed 20 Oct 2026.